-
公开(公告)号：EP3813858A1
公开(公告)日：2021-05-05
申请号：EP19826230.5
申请日：2019-06-28
发明人： DINH, Phuong-Uyen , CHENG, Ke
-
公开(公告)号：EP4344739A2
公开(公告)日：2024-04-03
申请号：EP23205669.7
申请日：2019-06-28
发明人： CHENG, Ke , DINH, Phuong-Uyen
IPC分类号： A61P11/00
摘要： Idiopathic pulmonary fibrosis (IPF) is currently the most fatal form of idiopathic interstitial lung disease in which persistent lung injuries result in scar tissue formation. Provided are methods and compositions for the treatment of pulmonary conditions such as fibrosis. Lung spheroid cell-derived conditioned media (LSC-CM) and exosomes (LSC-EXO) are used to treat different models of lung injury. Inhalation treatment with LSC-CM and LSC-EXO-derived compositions can attenuate and/or reverse bleomycin- and silica-induced fibrosis, reestablish normal alveolar structure and decrease extracellular matrix accumulation.
-
公开(公告)号：EP4344739A3
公开(公告)日：2024-05-29
申请号：EP23205669.7
申请日：2019-06-28
发明人： CHENG, Ke , DINH, Phuong-Uyen
CPC分类号： A61K35/42 , A61K38/00 , A61K9/0075 , A61K9/19 , C12N2513/0020130101 , C12N5/0689 , A61K31/713 , A61P11/00
摘要： Idiopathic pulmonary fibrosis (IPF) is currently the most fatal form of idiopathic interstitial lung disease in which persistent lung injuries result in scar tissue formation. Provided are methods and compositions for the treatment of pulmonary conditions such as fibrosis. Lung spheroid cell-derived conditioned media (LSC-CM) and exosomes (LSC-EXO) are used to treat different models of lung injury. Inhalation treatment with LSC-CM and LSC-EXO-derived compositions can attenuate and/or reverse bleomycin- and silica-induced fibrosis, reestablish normal alveolar structure and decrease extracellular matrix accumulation.
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
